- Coronary Stents Coronary Balloons Catheters Guide Wires Introducer Sheaths Accessories Peripheral Interventional Products
- Immunoassay Molecular Diagnostics Hematology Diagnostics POCT Lab Solution
- Structural Heart Diseases Products
- Vascular Access Blood Pressure Transducer Arterial Blood Sampler CVC Accessories IV Catheter Needle-free Connectors Insulin Injection Pain Relief
- Hemodialysis consumables Hemoperfusion Cartridge Dialysis machine
- ECG Patient Monitor Oximeter
- Cardiovasculars Oncology Anti-infectives Central Nervous System Others
- Endoscope Endoscopic Ultrasound System
- Trauma Implant Spinal Implant Artificial Joint Sports Medicine
- Pacemakers and Leads Equipments
- Metabolic Diseases Cardiovascular Diseases
- ELISA CLIA FIA
- Nucleic Acid Extraction Nucleic Acid Extraction ＆ PCR Kits Real-Time PCR
- Thrombelastography Analyzer Blood Grouping Platelet Aggregation
- POCT - FIA Colloidal Gold
- NeoECG Holter Monitor Portable ECG Monitor AI-ECG Pocket ECG
- Patient Monitor Vital Signs Monitor End-tidal Capnography
- Fingertip Oximeter Handheld Oximeter Wrist Oximeter Wearable Oximeter All-in-One Health Monitor POCT Solution
- OBS Locking Compression Plate Locking Plates Conventional Plates Mini Plates System Screws Patella Ring - Patented Product Metal Pins Cable System
- Internal Fixation System Laminoplasty Plate System Percutaneous Kyphoplasty Fusion Cage Cervical Fixation System
- Hip System Knee System
- Suture Anchor Suture Button
MWN109
Clinical Trials
View on ClinicalTrials.gov
View on ClinicalTrials.gov
Two Formulations
MWN109 Injection | MWN109 Tablet | |
Route | Subcutaneous | Oral |
Dosing | Once weekly | Once daily |
Mechanism | GLP-1/GIP/GCG | GLP-1/GIP/GCG |
Indication | Overweight & obesity | Overweight & obesity |
Development | Phase III | Phase II |
Key differentiation | Advanced clinical development | Needle-free administration |
Development Highlights
1. Triple-Receptor Agonism
Designed to simultaneously activate GLP-1, GIP and GCG receptors, integrating complementary mechanisms involved in glycemic control, appetite regulation and energy expenditure in a single therapeutic approach.
2. Dual-Formulation Strategy
Available as both a once-weekly injectable and a once-daily oral formulation, providing complementary administration options and extending the potential of triple-agonist therapy from injectable to needle-free oral treatment.
3. Advanced Clinical Development
The injectable formulation has advanced to Phase III development in overweight and obesity, while the oral formulation provides a differentiated follow-on opportunity, supporting the development of a broader MWN109 metabolic franchise.
Thank You for Your Attention on Lepu Medical!
Email us with any questions or inquiries or use our contact data. We would be happy to answer your questions.
